Vulvovaginal candidiasis (VVC) is a very common infection that affects a great number of women at reproductive age and the frequent cause of taking gynecological medical consultation. The recurrent vulvovaginal candidiasis (RVVC) is a more severe condition that affects 5-8% of these patients; and the reasons are poorly understood ([@B21], [@B5]). *Candida albicans* is the most common causal agent but non-*albicans* species have been identified ([@B17], [@B21]). Among *C.*non-*albicans*, *Candida glabrata* and *Candida tropicalis* had been related with RVVC cases. Interestingly, *C. glabrata* isolates present lower azoles susceptibility than other species ([@B17], [@B21]).

The VVC and RVVC therapeutics are performed by topic application of polyene and azole agents ([@B20], [@B21]). Oral fluconazole (FLZ) has also been frequently used being the first drug of choice for VVC treatment ([@B20]), and the Public Health Service in Brazil furnishes it to the patients with VVC or RVVC. It is important to highlight the reliable identification of*C.* non-*albicans* because they had shown highest minimal inhibitory concentration (MIC) values to many antifungal agents ([@B17], [@B21], [@B14], [@B16]). The aim of this report was to identify species of *Candida* clinical isolates from women diagnosed with RVVC and their partners; and to evaluate the FLZ susceptibility.

From July 2005 to August 2011, 2,026 female patients ranging from 18-65 years old were evaluated at Gynecologic Services of three private and two public Services in São Paulo city, São Paulo state, Brazil. Out of 172 patients who presented VVC, 13 women with RVVC and their partners were selected for this study. Secretion of the ectocervice and vagina from the women and of the foreskin and glans from their respective partners were collected with moistened swabs in sterile saline solution. In this study women with diabetes mellitus, on steroid, antibiotics or hormone therapy, in use of intrauterine device using vaginal douches or spermicidal, carriers of immunodeficiency virus were excluded. All procedures were previously approved by the Research Ethic Committee of São Paulo Hospital, Federal University of São Paulo, São Paulo, Brazil (Protocol CEP 1719/05).

Samples were previously cultivated in CHROMagar *Candida* medium® (Becton-Dickinson, New Jersey, USA) at 37ºC for 48 h and isolated yeasts were transferred to Sabouraud dextrose agar (Difco, USA) for further procedures. Morphological, biochemical and physiological characterisation of the isolates were defined according to [@B9]. In order to confirm phenotypic identification, the isolates were submitted to molecular analysis. The DNA extractions and amplifications by polymerase chain reaction (PCR) were performed using *Candida* species-specific primers ([Table](#t1){ref-type="table"}) following protocols reported elsewhere ([@B13], [@B22]). Samples that were not identified by PCR were submitted to sequencing of the amplified products obtained with primers VLG/LS and ITS1/ITS4 ([@B23]), and the sequence similarity searches were done by BLAST (<http://www.ncbi.nlm.nih.gov/blast>).

TABLEPrimers used in polymerase chain reaction and random amplified polymorphic DNA assays: sequences, hybridisation temperature (annealing) and molecular weight of amplified productsPrimersSequencesAnnealingMolecular weightReferenceITS1/4F: 5'TCCGTAGGTGAACCTGCGG 3' R: 5'TCCTCCGCTTATTGATATGC 3'47ºCvariable14*Candida albicans* 1/2F: 5'TTTATCAACTTGTCACACCAGA-3' R: 5'ATCCCGCCTTACCACTACCG-3'55ºC272pb14*Candida glabrata* 1/2F: 5'TTATCACACGACTCGACACT-3' R: 5'CCCACATACTGATATGGCCTACAA-3'52ºC423pb14*Candida tropicalis* 1/2F: 5'CAATCCTACCGCCAGAGGTTAT-3' R: 5'TGGCCACTAGCAAAATAAGCGT-3'52ºC357pb14[^1]

Twenty-six yeasts were isolated from 13 samples of women diagnosed with RVVC and from 13 samples of their partners. *C. albicans* (14), *Candida duobushaemulonii* (6), *C. glabrata* (4), and *C. tropicalis* (2) isolates were identified by phenotypic characteristics and confirmed by molecular methods. The identification of *C. albicans, C. glabrata* and *C. tropicalis* were confirmed by PCR assays and the remaining isolates (n = 6) were accurately identified as *C. duobushaemulonii* by sequencing of the region ITS of rDNA, showing 100% of identity with a reference strain available in GenBank (NCBI Reference Sequence NR130694.1). The isolates of *C. duobushaemulonii* obtained from samples collected from the three couples were evaluated by random amplified polymorphic DNA (RAPD) assay employing the primer OPG10 and amplification parameters previously described ([@B18]); the yeast isolates demonstrated highly similar band patterns between isolates obtained of each couple ([Figure](#f01){ref-type="fig"}). Thus, the *C. duobushaemulonii* isolated from the women with RVVC and from their partners were possibly the same isolates.

Random amplified polymorphic DNA banding pattern of *Candida duobushaemulonii* recovered from the three couples with the primer OPG 10. Lane M: molecular weight marker 1 Kb (arrow) (Fermentas, USA); Lines 1-2: *C. duobushaemulonii* isolated from the couple 1; Lines 3-4: *C. duobushaemulonii* isolated from the couple 2; and Lines 5-6: *C. duobushaemulonii* isolated from the couple 3.

*C. albicans*, *C. glabrata* and *C. tropicalis* have been commonly identified in RVVC ([@B17], [@B21]). Here, we identified the three *Candida* species and also *C. duobushaemulonii* from genital samples of women and their partners. The infection of *Candida haemulonii* complex species (including *C. duobushaemulonii*) is not common in humans. Lehman et al. (1993) reported variations among *C. haemulonii* isolates and concluded that the isolates represented a complex of *C. haemulonii* group I and*C. haemulonii* group II species. In 2012, [@B3] proposed a reclassification of the isolates of group II as *C. duobushaemulonii.* Classical and commercial methods of yeast identification are not reliable to identify rare and emerging clinical isolates of *C. haemulonii* complex species as *C. haemulonii, Candida pseudohaemulonii*, *Candida auris* and *C. duoboshaemulonii* ([@B7],[@B3]). The identification at species level was achieved only after the sequencing of ITS region, which is in agreement with other authors ([@B3], [@B16]).

The first human isolation of *C. haemulonii* complex species occurred in 1984 from the blood of a patient with renal failure ([@B10]). These species are opportunistic fungal pathogens that have been associated with onychomycosis, finger nail infections and broncho-alveolar lavage ([@B16]), bloodstream infections ([@B19], [@B2], [@B14]), fungaemia related catheter ([@B8]), and with an outbreak in neonatal care units ([@B6]). Recently, [@B1] showed that among 14,642 positive yeast cultures from five hospitals in São Paulo (Brazil), 40 (0.3%) isolates were identified as *C. haemulonii* complex species. *C. duobushaemulonii* was characterised in nine biological samples and the data suggested that patients with diabetes mellitus are more likely to have positive cultures for *C. duobushaemulonii* ([@B1]).

In our study, the FLZ susceptibility testing of isolates was performed by the standard kit "E-Test" (Biodisk AB, Solna, Sweden) according to manufacturer recommendations. Reduced susceptibility to FLZ was observed for all isolates of *C. duobushaemulonii* (MIC ranging from 8-\>64 µg/mL), 50% of *C. glabrata* isolates exhibited resistance (≥ 64 µg/mL), and all isolates of*C. albicans* and *C. tropicalis* were susceptible to FLZ. The antifungal susceptibility interpretation was based on the breakpoint values for FLZ recommended by the [@B4]. The reduced susceptibility to FLZ of *C.* non-*albicans* species in RVVC cases described in this report, mainly *C. glabrata* and *C. duobushaemulonii*, is in agreement with other authors ([@B3], [@B1]). *C. duobushaemulonii* species complex have been isolated from several clinical sources varying from superficial to deep infections ([@B2], [@B16]) and they are related with lower susceptibility to polyenes, azoles and echinocandins ([@B16], [@B1]).

FLZ is the main antifungal agent employed in VVC; and for RVVC 10-14 days of induction therapy with a topical agent or oral FLZ, followed by FLZ, 150 mg weekly for six months, is strongly recommended ([@B20], [@B15]). In our research FLZ was used for its effectiveness and because it is recommended and furnished by the Public System of Health in Brazil for RVVC treatment. In our experience, RVVC presented clinical and mycological resolution after symptomatic and asymptomatic partner's treatment and the use of antifungal drugs for a long time.

The RVVC is a clinical condition that is characterised by three or more episodes of VVC with the isolation of the causal agent that occurs within a 12-months period. It is known that the causes of RVVC are multifactorial ([@B21]). The knowledge about the relation of sexual activity with the infection is limited. The role of sexual partners, trauma of the vaginal mucosa, immunosuppressive effect of semen during sexual activity besides other factors should be taken into consideration in the cases of repetition ([@B12]). Studies that collect more specimens and detailed clinical data from women with RVVC may enhance the ability to distinguish between recurrence and reinfection. In all cases of RVVC of our investigation, there was 100% of agreement among *Candida* spp. isolated from the couples as demonstrated by the RAPD assay, that may suggest transmission between partners. Investigations did not prove the sexual acquisition of genital candidiasis ([@B20], [@B12], [@B5]). So, the real role of sexual transmission on RVVC has yet to be defined.

In summary, in these 13 cases of RVVC we emphasise the importance of the correct identification of emergent pathogens that had shown higher MIC values for routine antifungal drugs as FLZ. To our best knowledge, it is the first isolation of *C. duobushaemulonii*, a rare human emergent pathogen, from RVVC cases with the accurate identification of the fungal agent. We highlight the reduced susceptibility of this species to FLZ, which represents a major therapeutic choice for RVVC. All these informations will be very useful to improve the management of the patients with infections caused by these organisms and will contribute to the surveillance of RVVC.
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[^1]: F: forward; R: reverse.
